findmyKOL

Hilary Dubrock, MD

Enriched profile

Associate Professor of Medicine, Division of Pulmonary and Critical Care Medicine; Program Director, Pulmonary Hypertension Fellowship · Mayo Clinic

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Rochester, MN · Midwest · United StatesSpecialtyPulmonary DiseaseFocusPulmonary Hypertension Research and Treatments+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Hilary Dubrock is Associate Professor of Medicine, Division of Pulmonary and Critical Care Medicine; Program Director, Pulmonary Hypertension Fellowship at Mayo Clinic. OpenAlex indexes 181 publications with 2,376 citations (h-index 24); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 16 Oct 2026

Overview

Updated 18 Oct 2026

Hilary Dubrock, M.D., is Associate Professor of Medicine, Division of Pulmonary and Critical Care Medicine at Mayo Clinic, Rochester, Minnesota. The public record shows 181 publications with 2,376 citations (h-index 24), centered on Pulmonary Hypertension Research and Treatments, Liver Disease and Transplantation, Vascular Anomalies and Treatments. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 4 companies.

  • Most recent indexed publication: 2026 · Journal of the American Heart Association
  • Top research focus: Pulmonary Hypertension Research and Treatments
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 4 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Pulmonary Hypertension2 trialsHepatopulmonary Syndrome2 trialsHypertension2 trialsPulmonary Arterial Hypertension1 trial

Research focus

OpenAlex concept fingerprint
Pulmonary Hypertension Research and TreatmentsLiver Disease and TransplantationVascular Anomalies and TreatmentsOrgan Transplantation Techniques and OutcomesTransplantation: Methods and Outcomes

Drugs & molecules

across trials, industry payments and publications
Remodulingeneric · TreprostinilClinical trials—Industry payments1Publications3Winrevairgeneric · SotaterceptClinical trials—Industry payments40Publications—Opsumitgeneric · MacitentanClinical trials—Industry payments17Publications—Uptravigeneric · SelexipagClinical trials—Industry payments12Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments54Actelion Pharmaceuticals US, Inc.Clinical trials—Industry payments23United Therapeutics CorporationClinical trials—Industry payments9Janssen Scientific Affairs, LLCClinical trials—Industry payments5Mayo ClinicClinical trials4Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
181publications

Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.

2,376citations

Total citations across indexed works.

24h-index

Hirsch index (OpenAlex). i10-index 48.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
4companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

All 4 trial records: search, sort and filter.Explore →

Industry payments

Updated 18 Oct 2026

4 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 10 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    68.8%
    Endothelin Receptor Antagonist28.4%
    Opsumit74%Ambrisentan20%Letairis6%
    Part D<11 patients
    Soluble Guanylate Cyclase Stimulator17.6%
    Adempas100%
    Part D≥21 patients

    + 6 more classes in this area

  • Genitourinary & hormones

    16.7%
    Phosphodiesterase 5 Inhibitor16.7%
    Sildenafil Citrate68%Tadalafil32%
    Part D<11 patients

  • Blood & clotting

    13.2%
    Prostacycline Vasodilator9.9%
    Tyvaso Dpi100%
    Part D≥26 patients
    Prostacyclin Receptor Agonist3.3%
    Uptravi100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)29.6% facility · 70.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 18 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 24 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction
    Article353 citations2017
    doi.org ↗
  2. 02
    Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study
    Article150 citations2021
    doi.org ↗
  3. 03
    Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications
    Article146 citations2022
    doi.org ↗
  4. 04
    High-sensitivity C-reactive protein in heart failure with preserved ejection fraction
    Article135 citations2018
    doi.org ↗
  5. 05
    Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Article127 citations2024
    doi.org ↗
All 181 cited works: search, sort and filter.Explore →

Network

Updated 18 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Michael J. Krowka58Robert P. Frantz53Hector R. Cajigas26Stephen C. Mathai21Charles D. Burger18Kathryn T. del Valle18Evelyn M. Horn16Anna Ryan Hemnes15Rodrigo Cartin‐Ceba15Steven M. Kawut13Nadine Al‐Naamani13Yogesh N.V. Reddy12Franz P. Rischard12Barry A. Borlaug11Erika B. Rosenzweig11Julie K. Heimbach10Garvan C. Kane10Michael B. Fallon10James R. Runo10Kimberly A. Forde9Katherine Carlson9David B. Badesch9Richard N. Channick9Sonja Bartolome9Peter M. Classi9Aaron B. Waxman8SERPIL CEM ERZURUM8Thenappan Thenappan8Matthew R. Lammi8Jane A. Leopold8Karen L. Krok8Andrew C. Nelsen8Teresa De Marco8Vivek Iyer8Jeffrey S. Sager7Paul M. Hassoun7Gerald J. Beck7Margaret M. Redfield7Steven D. Nathan7Nicholas S. Hill7

Online presence

Updated 18 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/hilary-dubrock-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    breatheeasy.transistor.fm/people/hilary-dubrock-md-mmsc

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breatheeasy.transistor.fm ↗
  • Other

    phawarepodcast.libsyn.com/podcast/hilary-dubrock-md-phaware-interview-329

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →phawarepodcast.libsyn.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.